Developer docs
API playgroundTry for free, no card

Search company profiles

Prokarium

Full company profile

uuid00021os

Namestring
Prokarium
Legal namestring
Prokarium Limited
Websiteurl
prokarium.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Prokarium is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in London, UK, developing microbial immunotherapies for oncology using proprietary engineered Salmonella bacteria. The company's core technology is the ZH9 chassis strain, a genetically attenuated Salmonella enterica serovar Typhi that naturally targets tumors, overcomes the suppressive tumor microenvironment, and can be programmed via the Living Cures synthetic biology platform to deliver diverse therapeutic cargo. Its lead product ZH9 is being evaluated as an intravesical treatment for non-muscle invasive bladder cancer (NMIBC) in the ongoing Phase 1/1b PARADIGM-1 trial (NCT06181266) at multiple US clinical sites, with interim data showing 91% freedom-from-relapse at 12 months and a favorable safety profile. The pipeline extends to muscle invasive bladder cancer (in combination with checkpoint inhibitors), the IO Prime oral immune fitness agent, and the Living Cures discovery platform for cargo-delivery IO therapeutics.

The company monetizes through future product sales post-regulatory approval and potential licensing agreements, as no commercial products are currently marketed. It operates an enterprise field sales motion targeting healthcare providers and clinical trial sites, distributes investigational therapies through clinical trial sites, and relies on scientific conference presence (AUA, EAU, SITC, AACR, BIO) for clinical and scientific community engagement. Strategic partnerships underpin its capabilities: an exclusive worldwide license with Lausanne University Hospital (CHUV) for Salmonella-based bladder cancer immunotherapy, a manufacturing contract with Wacker Biotech for GMP production, a bactofection platform collaboration with Ginkgo Bioworks, and a synthetic biology collaboration with Imperial College London's London Biofoundry.

Prokarium has raised over $60M across equity and grant funding rounds since 2018, including a $10M Series A (2018), a $21M Series B led by Korea Investment Partners (2020), and a $30M financing round (2023), with non-dilutive support from Wellcome Trust and UKRI. Backers include Riyadh Valley Company, Flerie Invest, Korea Investment Partners, and the UK government's Future Fund. The leadership team includes CEO Ibs Mahmood (appointed November 2025), CSO Livija Deban, COO Dara Henry, CMO Josi Holz, CFO Julia Jones, and Chairman Thomas Eldered (President of Flerie Invest).

Short descriptiontext

Prokarium is a London-based clinical-stage biopharmaceutical company developing engineered Salmonella-based microbial immunotherapies for oncology, with its lead candidate ZH9 in a Phase 1/1b trial for non-muscle invasive bladder cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbial immunotherapy, cancer immunotherapy, bladder cancer treatment, synthetic biology platform, live biotherapeutic products
Industry4 codes
PRIMARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Microbial Oncology Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Licensing
TypeOne Time License
Description

Prokarium is a clinical-stage biopharmaceutical company developing microbial immunotherapy treatments. Revenue will be generated through product sales following regulatory approval, with potential for licensing agreements and partnerships.

prokarium.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Prokarium develops engineered live-bacterial immunotherapies for solid tumors, led by ZH9, an intravesical attenuated Salmonella Typhi therapy for non-muscle invasive bladder cancer currently in a Phase 1/1b PARADIGM-1 trial in the United States. The company builds on its proprietary ZH9 chassis strain and its Living Cures synthetic biology platform to program bacteria as off-the-shelf, scalable immunotherapies and vaccine vectors, with additional pipeline programs including IO Prime (oral immune fitness agent) and the historical Entervax bivalent oral typhoid vaccine.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 91% freedom-from-relapse at 12 months in heavily pretreated NMIBC patients (10/11 patients at 12m per protocol completion)
+2 more records
Product overview1 text field

Prokarium is a clinical-stage biopharmaceutical company developing microbial immunotherapies for oncology using its Living Cures synthetic biology platform. The core product pipeline includes ZH9, an intravesical Salmonella-based immunotherapy for bladder cancer currently in Phase 1/1b trials, and IO Prime, an oral immune fitness agent ready for clinical entry. The Living Cures platform enables programmable bacterial therapeutics by engineering proprietary Salmonella strains (ZH9 chassis) to deliver diverse therapeutic cargo for solid tumors. Historical vaccine programs include Entervax for enteric fever. The company leverages the Vaxonella synthetic biology technology for vaccine development.

Product and service3 records
1ZH9
CategoryMicrobial immunotherapy / oncology biologic
Description

Proprietary live-bacterial immunotherapy based on an attenuated Salmonella enterica serovar Typhi (ZH9) strain, administered intravesically for non-muscle invasive bladder cancer (and being explored in muscle invasive bladder cancer in combination with checkpoint inhibitors). Currently in the Phase 1/1b PARADIGM-1 trial in the United States (NCT06181266) for NMIBC patients, including BCG-non-responsive patients.

2IO Prime
CategoryOral immuno-oncology biologic
Description

First-in-class oral immune fitness agent derived from the Living Cures / ZH9 platform, intended to restore immune function and potentiate cancer immunotherapy responses. Listed by Prokarium as ready to enter the clinic.

3Entervax
CategoryOral bivalent vaccine
Description

Bivalent oral vaccine against enteric fever (caused by Salmonella Typhi and Salmonella Paratyphi A), based on the proprietary Vaxonella thermostable microbial platform that enables oral, refrigeration-free vaccination. Previously advanced into Phase I clinical trials funded by the Wellcome Trust.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-01-09
Description

Partnership to develop a bactofection platform technology utilizing engineered bacteria to deliver RNA-based therapeutics. Ginkgo's microbial and mammalian foundry capabilities are being leveraged to engineer a Salmonella-based platform for delivering RNA payloads to treat cancer patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-02
Description

Exclusive worldwide license for the use of Salmonella immunotherapy in the treatment of bladder cancer. Collaboration initiated in 2019 with Department of Urology generating robust preclinical data package. Developed through collaboration with Dr. Denise Nardelli-Haefliger and team.

3London Biofoundry (Imperial College London)
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2022-01-26
Description

Multi-year agreement to work with researchers from Imperial College London to develop next-generation therapeutic candidates engineered to deliver payloads within the tumor microenvironment. Leverages London Biofoundry's synthetic biology stack and expertise.

prokarium.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-10-12
Description

Manufacturing contract for microbial immunotherapy for bladder cancer patients. Wacker Biotech using its LIBATEC technology platform for Live Microbial Products (LMPs) at Amsterdam site for GMP production of Salmonella-based immunotherapy.

Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage French company developing microbiome-derived and engineered bacterial immunotherapies for oncology. Comparable as a microbial immunotherapy company with a similar oncology focus and clinical-stage profile.

TypeEmerging player
Description

Developer of engineered phage- and microbiome-based precision therapeutics. Comparable to Prokarium in using synthetic biology to program microbes for therapeutic applications, though focused on phage delivery rather than Salmonella chassis.

TypeDirect peer
Description

Clinical-stage developer of C. novyi-NT, an engineered Clostridia-based bacterial cancer immunotherapy. Most directly comparable peer to Prokarium as a microbial immunotherapy company targeting solid tumors.

TypeDirect peer
Description

Swiss clinical-stage biotech using engineered Pseudomonas bacteria to deliver therapeutic proteins into tumors. Directly comparable as a bacterial cancer immunotherapy platform with a similar mechanism of action to Prokarium's ZH9.

TypeEmerging player
Description

Clinical-stage synthetic biology company developing engineered probiotic therapeutics (Synthetic Biotics). Comparable in its use of engineered living microbes as therapeutics and its clinical-stage status, though focused on metabolic and inflammatory diseases.

TypeEmerging player
Description

Clinical-stage developer of engineered bacteriophage therapies with CRISPR-payload capabilities. Comparable in its engineered-microbe therapeutic approach and synthetic biology platform, though focused on infectious disease and microbiome modulation.

TypeBroad incumbent
Description

Commercial-stage immuno-oncology company with Anktiva (N-803) approved for BCG-unresponsive NMIBC. A direct competitor in Prokarium's lead indication, with overlapping patient population and clinical use case.

TypeBroad incumbent
Description

Global pharmaceutical company with Adstiladrin (nadofaragene firadenovec) approved for BCG-unresponsive NMIBC. Direct NMIBC competitor with a gene therapy approach contrasting with Prokarium's microbial immunotherapy.

TypeBroad incumbent
Description

Large oncology incumbent with Keytruda (pembrolizumab) approved for BCG-unresponsive NMIBC. Sets the efficacy bar and standard-of-care comparison point for any new NMIBC entrant including Prokarium's ZH9.

10Novome Biotechnologies
TypeEmerging player
Description

Engineered-microbe therapeutics company (now part of Eligo) developing engineered bacterial strains for disease treatment. Comparable in its use of synthetic biology to program bacteria as living therapeutics.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prokarium

Microbial Oncology Immunotherapyprokarium.com

Prokarium is a London-based clinical-stage biopharmaceutical company developing engineered Salmonella-based microbial immunotherapies for oncology, with its lead candidate ZH9 in a Phase 1/1b trial for non-muscle invasive bladder cancer.

What Prokarium does

Prokarium is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in London, UK, developing microbial immunotherapies for oncology using proprietary engineered Salmonella bacteria. The company's core technology is the ZH9 chassis strain, a genetically attenuated Salmonella enterica serovar Typhi that naturally targets tumors, overcomes the suppressive tumor microenvironment, and can be programmed via the Living Cures synthetic biology platform to deliver diverse therapeutic cargo. Its lead product ZH9 is being evaluated as an intravesical treatment for non-muscle invasive bladder cancer (NMIBC) in the ongoing Phase 1/1b PARADIGM-1 trial (NCT06181266) at multiple US clinical sites, with interim data showing 91% freedom-from-relapse at 12 months and a favorable safety profile. The pipeline extends to muscle invasive bladder cancer (in combination with checkpoint inhibitors), the IO Prime oral immune fitness agent, and the Living Cures discovery platform for cargo-delivery IO therapeutics.

The company monetizes through future product sales post-regulatory approval and potential licensing agreements, as no commercial products are currently marketed. It operates an enterprise field sales motion targeting healthcare providers and clinical trial sites, distributes investigational therapies through clinical trial sites, and relies on scientific conference presence (AUA, EAU, SITC, AACR, BIO) for clinical and scientific community engagement. Strategic partnerships underpin its capabilities: an exclusive worldwide license with Lausanne University Hospital (CHUV) for Salmonella-based bladder cancer immunotherapy, a manufacturing contract with Wacker Biotech for GMP production, a bactofection platform collaboration with Ginkgo Bioworks, and a synthetic biology collaboration with Imperial College London's London Biofoundry.

Prokarium has raised over $60M across equity and grant funding rounds since 2018, including a $10M Series A (2018), a $21M Series B led by Korea Investment Partners (2020), and a $30M financing round (2023), with non-dilutive support from Wellcome Trust and UKRI. Backers include Riyadh Valley Company, Flerie Invest, Korea Investment Partners, and the UK government's Future Fund. The leadership team includes CEO Ibs Mahmood (appointed November 2025), CSO Livija Deban, COO Dara Henry, CMO Josi Holz, CFO Julia Jones, and Chairman Thomas Eldered (President of Flerie Invest).

Prokarium firmographics

Firmographics
Name
Prokarium
Legal name
Prokarium Limited
Website
https://prokarium.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Prokarium is a London-based clinical-stage biopharmaceutical company developing engineered Salmonella-based microbial immunotherapies for oncology, with its lead candidate ZH9 in a Phase 1/1b trial for non-muscle invasive bladder cancer.
Ownership category
akta.pro rank

Prokarium industry classification

Industry
Product category
Microbial Oncology Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Microbial immunotherapy
  • Cancer immunotherapy
  • Bladder cancer treatment
  • Synthetic biology platform
  • Live biotherapeutic products

Where Prokarium is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Prokarium business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Development and Licensing: Prokarium is a clinical-stage biopharmaceutical company developing microbial immunotherapy treatments. Revenue will be generated through product sales following regulatory approval, with potential for licensing agreements and partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Prokarium product offering

Product offering

Core offering

Prokarium develops engineered live-bacterial immunotherapies for solid tumors, led by ZH9, an intravesical attenuated Salmonella Typhi therapy for non-muscle invasive bladder cancer currently in a Phase 1/1b PARADIGM-1 trial in the United States. The company builds on its proprietary ZH9 chassis strain and its Living Cures synthetic biology platform to program bacteria as off-the-shelf, scalable immunotherapies and vaccine vectors, with additional pipeline programs including IO Prime (oral immune fitness agent) and the historical Entervax bivalent oral typhoid vaccine.

Product overview

Prokarium is a clinical-stage biopharmaceutical company developing microbial immunotherapies for oncology using its Living Cures synthetic biology platform. The core product pipeline includes ZH9, an intravesical Salmonella-based immunotherapy for bladder cancer currently in Phase 1/1b trials, and IO Prime, an oral immune fitness agent ready for clinical entry. The Living Cures platform enables programmable bacterial therapeutics by engineering proprietary Salmonella strains (ZH9 chassis) to deliver diverse therapeutic cargo for solid tumors. Historical vaccine programs include Entervax for enteric fever. The company leverages the Vaxonella synthetic biology technology for vaccine development.

Differentiator

Problem solved

Functional benefit

Products and services

  • ZH9 Proprietary live-bacterial immunotherapy based on an attenuated Salmonella enterica serovar Typhi (ZH9) strain, administered intravesically for non-muscle invasive bladder cancer (and being explored in muscle invasive bladder cancer in combination with checkpoint inhibitors). Currently in the Phase 1/1b PARADIGM-1 trial in the United States (NCT06181266) for NMIBC patients, including BCG-non-responsive patients.
  • IO Prime First-in-class oral immune fitness agent derived from the Living Cures / ZH9 platform, intended to restore immune function and potentiate cancer immunotherapy responses. Listed by Prokarium as ready to enter the clinic.
  • Entervax Bivalent oral vaccine against enteric fever (caused by Salmonella Typhi and Salmonella Paratyphi A), based on the proprietary Vaxonella thermostable microbial platform that enables oral, refrigeration-free vaccination. Previously advanced into Phase I clinical trials funded by the Wellcome Trust.

Quantifiable outcome

  • 91% freedom-from-relapse at 12 months in heavily pretreated NMIBC patients (10/11 patients at 12m per protocol completion)
  • +2 more outcomes

Companies that use Prokarium

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Prokarium technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Prokarium partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • Ginkgo BioworkscoreTechnology or Integration · 9 January 2023Partnership to develop a bactofection platform technology utilizing engineered bacteria to deliver RNA-based therapeutics. Ginkgo's microbial and mammalian foundry capabilities are being leveraged to engineer a Salmonella-based platform for delivering RNA payloads to treat cancer patients.
  • Lausanne University Hospital (CHUV)coreStrategic or Co-development Partner · 2 March 2022Exclusive worldwide license for the use of Salmonella immunotherapy in the treatment of bladder cancer. Collaboration initiated in 2019 with Department of Urology generating robust preclinical data package. Developed through collaboration with Dr. Denise Nardelli-Haefliger and team.
  • London Biofoundry (Imperial College London)supportingTechnology or Integration · 26 January 2022Multi-year agreement to work with researchers from Imperial College London to develop next-generation therapeutic candidates engineered to deliver payloads within the tumor microenvironment. Leverages London Biofoundry's synthetic biology stack and expertise.
  • Wacker BiotechcoreTechnology or Integration · 12 October 2021Manufacturing contract for microbial immunotherapy for bladder cancer patients. Wacker Biotech using its LIBATEC technology platform for Live Microbial Products (LMPs) at Amsterdam site for GMP production of Salmonella-based immunotherapy.

Scale indicators5 records

Recent moves13 records

Expansion highlights6 records

Prokarium competitors and assessment

Company assessment

Direct peers

  • Enterome: Clinical-stage French company developing microbiome-derived and engineered bacterial immunotherapies for oncology. Comparable as a microbial immunotherapy company with a similar oncology focus and clinical-stage profile.
  • BioMed Valley Discoveries: Clinical-stage developer of C. novyi-NT, an engineered Clostridia-based bacterial cancer immunotherapy. Most directly comparable peer to Prokarium as a microbial immunotherapy company targeting solid tumors.
  • T3 Pharmaceuticals: Swiss clinical-stage biotech using engineered Pseudomonas bacteria to deliver therapeutic proteins into tumors. Directly comparable as a bacterial cancer immunotherapy platform with a similar mechanism of action to Prokarium's ZH9.

Emerging players

  • Eligo Bioscience: Developer of engineered phage- and microbiome-based precision therapeutics. Comparable to Prokarium in using synthetic biology to program microbes for therapeutic applications, though focused on phage delivery rather than Salmonella chassis.
  • Synlogic: Clinical-stage synthetic biology company developing engineered probiotic therapeutics (Synthetic Biotics). Comparable in its use of engineered living microbes as therapeutics and its clinical-stage status, though focused on metabolic and inflammatory diseases.
  • Locus Biosciences: Clinical-stage developer of engineered bacteriophage therapies with CRISPR-payload capabilities. Comparable in its engineered-microbe therapeutic approach and synthetic biology platform, though focused on infectious disease and microbiome modulation.
  • Novome Biotechnologies: Engineered-microbe therapeutics company (now part of Eligo) developing engineered bacterial strains for disease treatment. Comparable in its use of synthetic biology to program bacteria as living therapeutics.

Broad incumbents

  • ImmunityBio: Commercial-stage immuno-oncology company with Anktiva (N-803) approved for BCG-unresponsive NMIBC. A direct competitor in Prokarium's lead indication, with overlapping patient population and clinical use case.
  • Ferring Pharmaceuticals: Global pharmaceutical company with Adstiladrin (nadofaragene firadenovec) approved for BCG-unresponsive NMIBC. Direct NMIBC competitor with a gene therapy approach contrasting with Prokarium's microbial immunotherapy.
  • Merck & Co. Large oncology incumbent with Keytruda (pembrolizumab) approved for BCG-unresponsive NMIBC. Sets the efficacy bar and standard-of-care comparison point for any new NMIBC entrant including Prokarium's ZH9.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Prokarium social profiles

Digital presence

Prokarium compliance and trust

Trust signal

Compliance2 records

Prokarium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prokarium leadership team

Management profile

Number of profiles

Profiles14 records

Prokarium funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prokarium M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prokarium

What does Prokarium do?

Prokarium develops engineered live-bacterial immunotherapies for solid tumors, led by ZH9, an intravesical attenuated Salmonella Typhi therapy for non-muscle invasive bladder cancer currently in a Phase 1/1b PARADIGM-1 trial in the United States. The company builds on its proprietary ZH9 chassis strain and its Living Cures synthetic biology platform to program bacteria as off-the-shelf, scalable immunotherapies and vaccine vectors, with additional pipeline programs including IO Prime (oral immune fitness agent) and the historical Entervax bivalent oral typhoid vaccine.

Is Prokarium a public or private company?

Prokarium is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prokarium founded?

Prokarium was founded in 2012. It employs 11 to 50 people.

Where is Prokarium based?

Prokarium is headquartered in London, United Kingdom, in the Europe region.

How does Prokarium make money?

One revenue line is on record: pharmaceutical Development and Licensing.

Who are Prokarium's main competitors?

Direct peers on record are Enterome, BioMed Valley Discoveries and T3 Pharmaceuticals. Emerging players are Eligo Bioscience, Synlogic, Locus Biosciences and Novome Biotechnologies. Broad incumbents are ImmunityBio, Ferring Pharmaceuticals and Merck & Co..

Does Prokarium have an API?

No public API is recorded for Prokarium.

What industry is Prokarium in?

Prokarium's product category is Microbial Oncology Immunotherapy. Its primary akta.pro industry code is HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection), with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerFlerie portfolio company reports positive interim data in bladder cancer studyFlerie's portfolio company Prokarium reported positive interim data from a bladder cancer study at the American Urological Association's annual meeting. The safety profile was favorable, and 91% of patients who completed the protocol remained recurrence-free after 12 months. The company says its microbial immunotherapy can be integrated into current standard-of-care protocols.Business Wire BlogProkarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early EfficacyProkarium reported interim data from its Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer patients, showing excellent safety and early efficacy. Of 22 patients, 91% were free from relapse at 12 months, with no grade 3 or higher toxicities. The company plans a larger phase 2 study across intermediate and high-risk populations.SeedtableExplore 69 Best Pharma Startups to watch in 2025. Discover innovative companies, funding insights, and industry trends.The article presents a curated list of six pharmaceutical and biotechnology startups to watch in 2025, highlighting their funding status and core technologies. Featured companies include Indee Labs, HistoSonics, Prokarium, Evox Therapeutics, and Roquette, covering areas such as CAR-T manufacturing, histotripsy, and synthetic biology vaccines.Business Wire BlogProkarium Appoints Ibs Mahmood as Chief Executive OfficerProkarium, a clinical-stage biopharmaceutical company based in London, has appointed Ibs Mahmood as Chief Executive Officer, succeeding Kristen Albright who will transition to the Board of Directors. Mahmood brings 25 years of biotechnology experience, having founded and led multiple life science companies and raising over $300 million for his own ventures. The company is advancing its lead immunotherapy program ZH9 in US clinical trials for non-muscle invasive bladder cancer, with the goal of transforming the treatment paradigm for the disease.Pulse 2.0Microbial Immunotherapy Company Prokarium Raises $30 MillionBiopharmaceutical company Prokarium announced the raising of $30 million in new funding to support its lead oncology program entering clinical development. This financing follows a strategic partnership with Ginkgo Bioworks to develop bactofection platform technology using proprietary Salmonella strains for treating difficult-to-treat cancers like bladder cancer.Pulse 2.0Microbial Immunotherapy Company Prokarium Raises $30 MillionProkarium raised $30 million in new funding, following its partnership with Ginkgo Bioworks to develop a bactofection platform. The company will use the proceeds to fund its lead oncology program entering clinical development this year and expand its platform for delivering novel therapeutic payloads.BusinessCloud£25m backing for MedTech ProkariumProkarium raised £25 million in new funding to advance its lead oncology program for bladder cancer. The company will use the proceeds to enter clinical development this year and expand its platform for delivering RNA therapeutics. It also announced a partnership with Ginkgo Bioworks to develop a bactofection platform.FinSMEsProkarium Raises $30M in FundingLondon-based biopharmaceutical company Prokarium raised $30 million in funding to support the clinical development of its oncology candidate for non-muscle invasive bladder cancer. The capital will also be used to accelerate platform discovery efforts, following a recent partnership with Ginkgo Bioworks to develop bactofection technology.ForbesMicrobial Immunotherapy Company Prokarium Raises $30M On Heels Of Ginkgo Bioworks PartnershipLondon-based biopharma company Prokarium has raised $30 million in a financing round led by Flerie Invest to advance its microbial immunotherapy program for bladder cancer. This funding follows a strategic partnership with Ginkgo Bioworks announced on January 9, 2023, which will allow Prokarium to utilize Ginkgo's synthetic biology infrastructure to reprogram its engineered Salmonella strains for next-generation cancer therapeutics.BioSpaceProkarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic PlatformProkarium, a biopharmaceutical company focused on microbial immunotherapy, has raised $30 million in funding to support the clinical development of its lead oncology candidate for non-muscle invasive bladder cancer. The financing aims to facilitate the delivery of novel therapeutic payloads and leverage a partnership with Ginkgo Bioworks to enhance its technological capabilities. The company's lead program seeks to transform bladder cancer treatment, targeting a market that has seen little innovation in over three decades.